Company: MBIO
Filing Date: 2025-02-05
Form Type: S-1/A
Source: 0001104659-25-009408
Chunk: 173

Company: MUSTANG BIO, INC.
Filing Date: 2025-02-05
Form: S-1/A
Chunk 173
---
 the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and our stockholders. Further, a stockholder’s investment may be adversely affected to the extent that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. At present, there is no pending litigation or proceeding involving any of our directors, officers or employees for which indemnification is sought and we are not aware of any threatened litigation that may result in claims for indemnification. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors, officers or control persons, in the opinion of the SEC, such indemnification is against public policy, as expressed in the Securities Act and is therefore unenforceable.

107

EXECUTIVE AND DIRECTOR COMPENSATION Summary Compensation Table As determined in accordance with SEC rules, our named executive officers (“NEOs”) set forth below, which includes all executive officers serving during 2024. The following table sets forth information concerning compensation paid by us to our NEOs for their services rendered to us in all capacities during the years ended December 31, 2024 and 2023.

| ​                                                                      
 ​                                                                      
 ​                                                                      
 Name and Principal Position                                            | ​ 
 ​ 
 ​ 
 ​ |    ​ 
    ​ 
 Year | ​ 
 ​ 
 ​ 
 ​ | ​      
 Salary 
 ($)    |         | ​ 
 ​ 
 ​ 
 ​ | ​     
 Bonus 
 ($)   |   | ​    
 ​    
 ​    | Stock      
 Awards (1) 
 ($)        |        | ​ 
 ​ 
 ​ 
 ​ | Option 
 Awards 
 ($)    |   | ​ 
 ​ 
 ​ 
 ​ | Non-Equity     
 Incentive Plan 
 Compensation   
 ($)            |   | ​ 
 ​ 
 ​ 
 ​ | All Other    
 Compensation 
 ($)          |         | ​ 
 ​ 
 ​ 
 ​ | ​     
 Total 
 ($)   |         |
|:-----------------------------------------------------------------------|:--|-----:|:--|:-------|--------:|:--|:------|:--|:-----|:-----------|-------:|:--|:-------|:--|:--|:---------------|:--|:--|:-------------|--------:|:--|:------|--------:|
| Manuel Litchman, M.D. (3)                                              | ​ | 2024 | ​ | $      | 501,704 | ​ |